The 2022 BSR guideline for the treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs

The 2022 British Society for Rheumatology guideline for the treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs

Objectives:
This guideline offers systematic and evidence-based recommendations to support UK clinicians in the prescription of bDMARD and tsDMARD therapies in adults with PsA. The guideline also includes guidance for managing those patients with extra-articular manifestations [uveitis and inflammatory bowel disease (IBD)], as well as those who smoke or are overweight. The guideline provides a stepwise management plan giving clear advice on treatment, including drug eligibility, sequencing, switching and treatment strategy.

This guideline complements existing BSR guidelines and therefore does not include:
- detailed assessment of the safety of bDMARDs;
- biologic or tsDMARD therapies for juvenile idiopathic arthritis;
- use of csDMARDs in PsA;
- use of biologics or tsDMARDs in pregnancy; or
- biologic or tsDMARD therapies for adults with psoriatic disease confined to the skin only (in this situation, please refer to BAD guidelines for management of psoriasis at https://www.bad.org.uk/healthcare-professionals/psoriasis).


Read full Guideline